However, since the DESTINY-Breast03 trial showcased the efficacy of trastuzumab deruxtecan in this setting last year, this agent is now considered the preferred second-line treatment with T-DM1 as an alternative option.ĭESTINY-Breast03 was an open-label, multicenter study that enrolled patients with unresectable or metastatic HER2-positive breast cancer.
#T dm1 breast cancer plus
Study authors noted that the first-line standard of care for HER2-positive metastatic breast cancer had been established to be trastuzumab plus taxane with pertuzumab in the CLEOPATRA trial and that the EMILIA trial established T-DM1 as the standard of care after trastuzumab and a taxane for metastatic, HER2-positive breast cancer in the second-line setting and beyond. Hurvitz, MD, a medical oncologist at the University of California, Los Angeles, said in a presentation of the data.“ reduced the risk of death by 36%, median PFS was nearly 4 times greater with than with TDM-1 and 78.5% of patients experienced a confirmed objective response.” “Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in OS versus TDM-1 as well as continued PFS benefit,” Sara A. According to updated results from the phase 3 DESTINY-Breast03 trial (NCT03529110) presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan-nxki (Enhertu) compared with ado-trastuzumab emtansine (Kadcyla T-DM1).Īt a median follow-up of 28.4 months (range, 0.0-46.9), the median overall survival (OS) was not reached (NR 95% CI, 40.5-not evaluable ) in the trastuzumab deruxtecan arm (n = 261) compared with NR (95% CI, 34.0-NE) in the 263-patient T-DM1 arm (HR, 0.64 95% CI, 0.47-0.87 P =.
0 kommentar(er)
